UC Riverside study may lead to new treatments for multiple sclerosis. Multiple sclerosis (MS) affects an estimated 2.3 ...

TG Therapeutics, Inc.'s BRIUMVI saw Q1 2025 revenue surge 137% YoY. Click to learn about TGTX growth, upcoming trials, and ...

Lisa Pratta was a sales rep for drug manufacturer Questcor then she became a whistleblower. She witnessed bribes and was screamed at to illegally sell a multiple sclerosis drug. So she went ...

Children most affected by MS-related biological aging appeared to be aging up to two years faster than kids without MS, even ...

TG Therapeutics, Inc. announced new data presentations for BRIUMVI® (ublituximab-xiiy) at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, highlighting its efficacy for ...

Multiple sclerosis (MS) is a chronic, lifelong condition for which there is no cure. It causes progressive, irreversible disability, and many symptoms including pain, chronic fatigue, unsteady gait, ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with their disorder, a new clinical trial suggests. The drug, tolebrutinib ...

The results of this study signal a new chapter in multiple sclerosis because we finally found a potential way to treat non-relapsing secondary progressive forms.” Dr Fox is a paid advisor to ...

Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults Primary progressive MS, in adults ...

There are 4 main types of multiple sclerosis (MS), which differ based on how the disease has progressed. The treatment options and long-term outlook can depend on your MS type.